Two Sigma Advisers
CMMB

Two Sigma Advisers’s Chemomab Therapeutics CMMB Stock Holding History

Two Sigma Advisers’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,525
Closed -$16.5K – 2321
2024
Q2 		$16.5K Sell
4,525
-4,925
-52% -$17K ﹤0.01% 2405
2024
Q1 		$29.4K Buy
9,450
+600
+7% +$1.54K ﹤0.01% 2378
2023
Q4 		$18.1K Buy
+8,850
New +$23.3K ﹤0.01% 2452
2023
Q2 		– Sell
-2,950
Closed -$18.8K – 2422
2023
Q1 		$18.8K Buy
+2,950
New +$23.1K ﹤0.01% 2523

Other funds holding CMMB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
YLHM
Yelin Lapidot Holdings Management Tel Aviv, Israel $480M AUM 42.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $8.11B AUM 24.74% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Two Sigma Advisers's CMMB Position: Q3 2024 in Review

Two Sigma Advisers sold out of Chemomab Therapeutics (CMMB) in Q3 2024, closing a stake of 4,525 shares — an estimated $16.5K sold.

Two Sigma Advisers first reported a position in CMMB in Q1 2023 and held it in 4 quarters. The position peaked at $29.4K in Q1 2024. 15 funds tracked by Wall St. Rank hold CMMB as of Q3 2024.

  • Two Sigma Advisers reported no remaining Chemomab Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Two Sigma Advisers sold 4,525 Chemomab Therapeutics shares in Q3 2024, an estimated $16.5K.
  • Two Sigma Advisers first reported a position in Chemomab Therapeutics in Q1 2023 and held it in 4 quarters.
  • Two Sigma Advisers's Chemomab Therapeutics position peaked at $29.4K in Q1 2024.
  • 15 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q3 2024.

Based on Two Sigma Advisers's 13F filing for Q3 2024, filed 14 Nov 2024.